Total funds raised by private biotechs in Europe fell to $831 million in 2011, down 17% compared with 2010, according to Elsevier’s Strategic Transactions database, as the region’s sovereign debt and currency crises compounded ongoing global financial uncertainty to depress sentiment.
A similar number of private biotech companies were successful in raising money in each of the past two years (41...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?